{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:44:38Z","timestamp":1790246678129,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.euo.2024.06.005","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T11:33:31Z","timestamp":1718796811000},"page":"1293-1302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["The Role of Mitomycin C in Intermediate-risk Non\u2013muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6126-9889","authenticated-orcid":false,"given":"Pietro","family":"Scilipoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"\u015alusarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Del","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Afferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Albisinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.06.005_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non\u2013muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.06.005_b0020","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0025","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00345-021-03908-x","article-title":"Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage","volume":"40","author":"Balasubramanian","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0030","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euf.2021.03.016","article-title":"Intravesical therapy in patients with intermediate-risk non\u2013muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence","volume":"8","author":"Laukhtina","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.06.005_b0035","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euo.2024.06.005_b0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0045","first-page":"CD011935","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"2020","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euo.2024.06.005_b0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2009.04.041","article-title":"Is intravesical bacillus Calmette-Gu\u00e9rin better than mitomycin for intermediate-risk bladder cancer?","volume":"56","author":"Dalbagni","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0060","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"10.1016\/j.euo.2024.06.005_b0065","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.euo.2024.06.005_b0070","unstructured":"Rohatgi A. WebPlotDigitizer \u2013 extract data from plots, images, and maps. https:\/\/automeris.io\/."},{"key":"10.1016\/j.euo.2024.06.005_b0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0080","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/03610918.2011.560732","article-title":"Confidence intervals for survival probabilities: a comparison study","volume":"40","author":"Yuan","year":"2011","journal-title":"Commun Stat Simulation Comput"},{"key":"10.1016\/j.euo.2024.06.005_b0085","article-title":"RoB 2: a revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2024.06.005_b0090","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2024.06.005_b0095","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0100","unstructured":"R Core Team. R: the R project for statistical computing. https:\/\/www.r-project.org."},{"key":"10.1016\/j.euo.2024.06.005_b0105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000474441","article-title":"Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma","volume":"31","author":"Schwaibold","year":"1997","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.euo.2024.06.005_b0115","first-page":"S79","article-title":"Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer","volume":"11","author":"Niijima","year":"1983","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.euo.2024.06.005_b0120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1464-410X.1993.tb15915.x","article-title":"Mitomycin-C in superficial bladder cancer. Is long-term maintenance therapy worthwhile after initial treatment?","volume":"71","author":"Hamdy","year":"1993","journal-title":"Br J Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0125","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0022-5347(01)67608-0","volume":"153","author":"Bouffioux","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0130","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.2011.39.2936","article-title":"Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial","volume":"30","author":"Lammers","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.06.005_b0135","first-page":"352","article-title":"Risk-based management of non-muscle invasive bladder cancer: experience from Tribhuvan University teaching hospital","volume":"14","author":"Luitel","year":"2016","journal-title":"Kathmandu Univ Med J"},{"key":"10.1016\/j.euo.2024.06.005_b0140","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4143\/crt.2005.37.1.44","article-title":"Comparison of 30 mg and 40 mg of mitomycin C intravesical instillation in Korean superficial bladder cancer patients: prospective, randomized study","volume":"37","author":"Jeong","year":"2005","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.euo.2024.06.005_b0145","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Gu\u00e9rin (BCG) in patients with non\u2013muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","article-title":"Hyperthermic mitomycin C in intermediate-risk non\u2013muscle-invasive bladder cancer: results of the HIVEC-1 trial","volume":"6","author":"Angulo","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.06.005_b0155","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0160","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000282849","article-title":"Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up","volume":"56","author":"Minervini","year":"1996","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2024.06.005_b0165","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.3390\/jcm10215105","article-title":"Long-term experience with hyperthermic chemotherapy (HIVEC) using mitomycin-C in patients with non-muscle invasive bladder cancer in Spain","volume":"10","author":"Plata","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2024.06.005_b0170","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bju.15571","article-title":"Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomized clinical trial","volume":"129","author":"Miyata","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.06.005_b0175","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0180","first-page":"139","article-title":"Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine","volume":"4","author":"Gao","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2024.06.005_b0185","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.euf.2018.08.019","article-title":"Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non\u2013muscle-invasive bladder cancer","volume":"4","author":"Tabayoyong","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.06.005_b0190","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: implications for clinical trial design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0195","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0090-4295(98)00212-X","article-title":"Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacillus Calmette-Gu\u00e9rin\u2013RIVM and mitomycin C in superficial bladder cancer","volume":"52","author":"Witjes","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.06.005_b0200","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin","volume":"156","author":"Krege","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non\u2013muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.005_b0210","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.euo.2023.07.012","article-title":"Oncological outcomes for patients with European Association of Urology very high-risk non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin or early radical cystectomy","volume":"6","author":"Contieri","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.06.005_b0215","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0029-7844(95)00251-L","article-title":"The problem of the type II statistical error","volume":"86","author":"Mittendorf","year":"1995","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.euo.2024.06.005_b0220","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/opo.12131","article-title":"When to use the Bonferroni correction","volume":"34","author":"Armstrong","year":"2014","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.euo.2024.06.005_b0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000472727","article-title":"Adjuvant intravesical chemotherapy of superficial bladder cancer with monthly doxorubicin or intensive mitomycin. A comparison of two consecutive series","volume":"13","author":"Ausfeld","year":"1987","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T19:11:46Z","timestamp":1737832306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124001524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2588931124001524"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.06.005","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Mitomycin C in Intermediate-risk Non\u2013muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}